

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)



(10) International Publication Number
WO 2021/247217 A1

(51) International Patent Classification:

A61P 9/00 (2006.01) *C07D 401/12* (2006.01)
A61P 11/00 (2006.01) *C07D 401/14* (2006.01)
A61P 13/12 (2006.01) *C07D 405/14* (2006.01)
A61P 25/00 (2006.01) *C07D 409/14* (2006.01)
A61P 29/00 (2006.01) *C07D 413/14* (2006.01)
A61P 35/00 (2006.01) *C07D 471/04* (2006.01)
A61P 37/08 (2006.01) *A61K 31/506* (2006.01)
C07D 249/06 (2006.01) *A61K 31/4439* (2006.01)
C07D 401/04 (2006.01)

(21) International Application Number:

PCT/US2021/032293

(22) International Filing Date:

13 May 2021 (13.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/034,220 03 June 2020 (03.06.2020) US
63/130,242 23 December 2020 (23.12.2020) US

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **BESTVATER, Brian P.**; 725 West 7th Avenue, Unit 105, Vancouver, British Columbia V5Z 1B9 (CA). **DU, Zhimin**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **FARAND, Julie**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **KAPLAN, Joshua A.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(72) Inventor: **PHILLIPS, Barton W.** (deceased).

(72) Inventors: **TANG, Doris T.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **VENKATARAMANI, Chandrasekar**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **WANG, Peiyuan**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **YANG, Kin S.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **ZAGORSKA, Anna**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: **BRINKER, Achim** et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: LPA RECEPTOR ANTAGONISTS AND USES THEREOF

(57) Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).



WO 2021/247217 A1